Trulieve Cannabis Corp. (TCNNF)
AI stock analysis · as of Jun 8, 2026
Loading microstructure…
Trulieve Cannabis is the largest US multi-state cannabis operator with 233 dispensaries (162 in Florida) generating ~$1.18B in revenue and $212M trailing FCF. The core investment question: do regulatory catalysts (Schedule III rescheduling eliminating 280E, Florida adult-use in 2026, NYSE uplisting) re-rate the stock, or does Florida concentration and federal enforcement risk keep it discounted? After a 17.5% single-day move and a triple from 52-week lows ($3.25 to $11.74), much of the optionality may already be priced in.
valuationFair-to-slightly expensive at $11.74: EV/EBITDA 7.8x and 8.9% FCF yield are attractive in isolation, but forward P/E ~49x and P/B 25x reflect that GAAP earnings recovery is entirely contingent on 280E relief; the stock is pricing in a meaningful probability of regulatory success.
This analysis is from Jun 8, 2026. Want the latest on TCNNF, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Schedule III rescheduling would eliminate IRC 280E, which currently disallows ordinary business expense deductions and creates effective tax rates far above statutory; news indicates this has moved forward, directly benefiting the medical-heavy book
- · Florida adult-use ballot initiative filed for November 2026 would convert Trulieve's 162-store FL network (70% of dispensary base) from medical-only to adult-use, a step-function revenue and margin event
- · Return to profitability and strong cash generation: $212M trailing FCF on ~$2.26B market cap = 8.9% FCF yield; Q1 2026 reportedly delivered $42M in FCF, demonstrating operating leverage
- · NYSE uplisting (confirmed June 2026) unlocks institutional ownership — currently only 11% institutional, 4.2% insider held — and improves liquidity/visibility
- · EV/EBITDA of 7.8x is reasonable for an operator with 60% gross margins and embedded regulatory call options; gross margin expanded from 52% (2023) to 60% (2025)
- · Insider activity is net neutral (zero net sells over 180d) — no signal of management bailing into the rally
Bear case
- · Three consecutive years of GAAP net losses (-$526M in 2023, -$155M 2024, -$116M 2025); revenue is flat-to-declining (-0.4% YoY in 2025, -3.7% trailing) — this is a regulatory bet, not an organic growth story
- · Extreme Florida concentration: 162 of 233 dispensaries in a single medical-only state; ballot failure in 2026 (Florida requires 60% supermajority and a prior initiative failed) would gut the bull thesis
- · Debt refinancing raised the cost of capital: retired 8% notes replaced with 10.5% notes due 2030; total debt $564M vs $256M cash, debt/equity 54.8x reflects badly impaired equity base
- · Goodwill impairment taken in Q3 2025 signals continued asset-value pressure; price/book of 25x is misleading given the writedowns
- · DEA rescheduling rulemaking was paused in January 2025 — the catalyst is real but timing is uncertain, and Rohrbacher-Farr medical protection only extended through January 30, 2026
- · Stock has tripled from 52-week lows and is +17.5% on the session; much of the rescheduling/uplist optionality appears priced in
- · Forward P/E of 48.9x prices in significant earnings recovery that depends on 280E relief actually materializing
Catalysts
- · DEA Schedule III final rule / rescheduling progress — single largest profitability lever
- · Florida adult-use ballot initiative qualification and November 2026 vote
- · NYSE uplisting completion June 2026 and subsequent institutional inclusion/index eligibility
- · Q2 2026 earnings (August 6, 2026) — first post-uplisting print, watch for 280E tax benefit recognition
- · Pennsylvania adult-use legislation in 2026 (21 dispensaries at stake)
- · Rohrbacher-Farr medical cannabis appropriations rider renewal (expires January 30, 2026)
Key risks
- · Florida 2026 ballot failure (requires 60% supermajority; 2024 initiative failed)
- · Schedule III rescheduling further delayed or blocked, leaving 280E tax burden intact
- · Federal enforcement risk if Rohrbacher-Farr rider lapses without renewal
- · Continued price compression in Maryland and other competitive markets eroding gross margins
- · Refinancing risk at 10.5% coupons amplifies leverage if FCF deteriorates
- · License renewal/compliance risk across eight states
What to watch
- · Q2 earnings August 6, 2026 — first post-NYSE-uplist print, watch margin trajectory and tax commentary
- · DEA rulemaking progress on Schedule III throughout 2026
- · Florida ballot petition signature count and certification progress
- · Rohrbacher-Farr rider renewal at January 30, 2026 deadline
- · Key technical levels: 52-week high $12.25 (resistance), prior congestion ~$7-8 (support)
- · Institutional ownership ramp post-NYSE listing — currently only 11%
Key metrics
Price target rationale
Base case $13.5 applies ~10x EV/EBITDA on modest improvement assuming partial 280E benefit and ballot uncertainty discount. Bull $22 assumes Schedule III enacted and Florida adult-use passes — re-rates to ~12-14x EV/EBITDA on materially higher EBITDA. Bear $6 reflects ballot failure, rescheduling delay, and re-rating back to distressed cannabis multiples (~5x EV/EBITDA) with leverage concerns reasserting.
On Wall Street's view (mixed): The lone sell-side target of $21 (79% upside) likely captures a successful Schedule III + Florida adult-use scenario, but with only one analyst covering and the stock already up 3x off lows, the consensus appears to fully assume regulatory wins without weighting failure scenarios. Directionally plausible if catalysts hit, but the single-analyst sample size and asymmetric framing make it unreliable.
Latest filing (10-K)
Trulieve is a bet on Florida adult-use legalization and federal rescheduling: with 162 dispensaries in a medical-only Florida market and a crushing 280E tax burden, both catalysts could transform profitability overnight, but neither is guaranteed.
Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida. It cultivates, manufactures, and retails cannabis products through 233 dispensaries across nine states (FL, AZ, PA, WV, OH, GA, MD, CT, CO). Revenue is generated primarily through retail dispensary sales of proprietary branded products, with a smaller wholesale component. Florida is the dominant market with 162 of 233 dispensaries, all operating under a medical-only framework.
What the news says · bullish
The dominant storyline for TCNNF is a confluence of major structural catalysts: Trulieve is uplisting to the NYSE (confirmed June 5, 2026), which is a significant liquidity and visibility event that directly triggered the stock surge noted on June 4. Simultaneously, the company is restructuring its corporate domicile from British Columbia to Delaware and deconsolidating its mixed-use Harvest arm to meet NYSE listing requirements. Underlying fundamentals are supportive, with Q1 2026 showing $42M in free cash flow and a return to profitability, while the Schedule III cannabis rescheduling removes the punishing 280E tax burden for medical operators — a direct tailwind for Trulieve's core business. The combination of exchange uplisting, regulatory relief, improving financials, and sector momentum makes this one of the more compelling near-term setups in cannabis, though execution risk and the historically volatile nature of cannabis equities warrant caution.
This analysis is from Jun 8, 2026. Markets move. Get the current read on TCNNF and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.